Ethical aspects of developments in neuroscience and drug addiction

Drugs and the Future

Volumn , Issue , 2007, Pages 439-465

  Ashcroft, Richard ^a   Campbell, Alastair V ^b   Capps, Ben ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38849084811     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012370624-9/50018-9     Document Type: Chapter

References (99)

1. Ashcroft R.E., Franey C. Further ethical and social issues in using a cocaine vaccine: response to Hall and Carter. J Med Ethics 2004, 30:341-343.
2. Ashworth A. Principles of criminal law 2003, Oxford University Press, Oxford. 4th edition.
3. Aust R., Condon J. Geographical variations in drug use: key findings from the 2001/2002 British Crime Survey 2003, Home Office, London.
4. Aust R., Smith N. Ethnicity and drug use: key findings from the 2001/2002 British Crime Survey 2003, Home Office, London.
5. Bosk C. Obtaining voluntary consent for research in desperately ill patients. Med Care 2002, 40(Supplement V-64-V-68).
6. The medical profession and human rights: handbook for a changing agenda 2001, British Medical Association (BMA), Zed Books and BMA, London.
7. Brownsword R. Causes for concern and causes of action: a comment on 'pushing drugs'. Washburn Law J 2003, 42:601-614.
8. Burke W., Atkins D., Gwinn D., Guttmacher A., Haddow J., Lau J., Palomaki G., Press N., Richards C.S., Wideroff L., Wiesner G.L. Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol 2002, 156:311-318.
9. Cami J. Drug addiction. N Engl J Med 2003, 349:975-986.
10. Campbell A.V. Education or indoctrination? The issues of autonomy in health education. Ethics in health care education 1991, Wiley, London. S. Doxiadis (Ed.).
11. Caplan A. No-brainer: can we cope with the ethical ramifications of new knowledge of the human brain?. Neuroethics: mapping the field 2002, 95-106. Dana Press, New York. S. Marcus (Ed.).
12. Caplan A. Is better best?. Sci Am 2003, 389:84-85.
13. Capron A. Ethical and human rights issues in research on mental disorders that may affect decision-making capacity. N Engl J Med 1999, 340:1430-1434.
14. Carnwarth T., Smith I. The heroin century 2002, Routledge, London.
15. Carrera M., Kaufmann G.F., Mee J.M., Meijler M.M., Koob G.F., Janda K.D. Treating cocaine addiction with viruses. Proc Natl Acad Sci 2004, 101:10416-10421.
16. Centre for Cognitive Liberty and Ethics (CCLE) Threats to cogitative liberty: pharmacotherapy and the future of the drug war 2004, CCLE, Davis, California.
17. Charland L. Cynthia's dilemma: consenting to heroin prescription. Am J Bioethics 2002, 2:37-47.
18. Cohen P.J. Immunisation for prevention and treatment of cocaine abuse: legal and ethical, implications. Drug Alcohol Depend 1997, 48:167-174.
19. Cohen P.J. Untreated addiction imposes an ethical bar to recruiting addicts for non-therapeutic studies of addictive drugs. J Law Med Ethics 2002, 30:73-81.
20. Coleman T. ABC of smoking cessation: use of simple and behavioral support. BMJ 2004, 328:397-399.
21. Copeland J. Barriers to formal treatment among women who self-managed change, in addictive behaviours. J Subst Abuse Treat 1997, 14:183-190.
22. Crabbe J.C., Phillips T.J. Genetics of alcohol and other abused drugs. Drug Alcohol Depend 1998, 51:61-71.
23. Crombag H., Robinson T.E. Drugs, environment, brain and behavior. Curr Dir Psychological Sci 2004, 13:107-111.
24. Danziger R. Discrimination gainst people with HIV and AIDS in Poland. BMJ 1994, 308:1145-1147.
25. Darke S., Hall W. Heroin overdose: Research and evidence-based intervention. J Urban Health 2003, 80:189-200.
26. Dean A., Moses G., Vernon J. Suspected withdrawal syndrome after cessation of St. John's wort. Annals Pharmacother 2003, 37:150.
27. Elliott C. Better than well: American medicine meets the American dream 2003, W.W. Norton, New York.
28. Ernst E. Herbal medicines: where is the evidence?. BMJ 2000, 321:395-396.
29. Ernst E. Herbal medicines put into context. BMJ 2003, 327:881-882.
30. Farah M. Emerging ethical issues in neuroscience. Nat Neurosci 2002, 5:1123-1129.
31. Farah M., Wolpe P. Monitoring and manipulating brain function: new neuroscience technologies and their ethical implications. Hasting Centre Report 2004, 43:35-45.
32. Farah M., Illes J., Cook-Deegan R., Gardner H., Kandel E., King P., Parens E., Sahakian B., Wolpe P. Neurocognitive enhancement: what can we do and what should we do?. Nat Rev Neurosci 2004, 5:421-425.
33. French M.T., Roebuck M.C., Alexandre P.K. To test or not to test: do workplace drug testing programmes discourage employee drug use?. Soc Sci Res 2004, 33:45-63.
34. Fukuyama F. Our posthuman future: consequences of the biotechnology revolution 2002, Farrar Straus and Giroux, New York.
35. Garges H., Varia I., Doraiswamy M. Cardiac complications and delirium associated with valerian root withdrawal. J Am Med Assoc 1998, 280:1566-1567.
36. Gems D. Book reviews: the face of the future: enhancing human traits: ethical and social implications. Nature 1999, 397:222-223. E. Parens (Ed.).
37. Godding V., Bonnier C., Fiasse L., Michel M., Longueville E., Lebecque P., Robert A., Galanti L. Does in utero exposure to heavy maternal smoking induce nicotine withdrawal symptoms in neonates?. Ped Res 2004, 55:645-651.
38. Hall W. The prospect for immunotherapy in smoking cessation. Lancet 2002, 360:1089-1091.
39. Hall S. The quest for a smart pill. Sci Am 2003, 289:36-45.
40. Hall W. Feeling 'better than well'. MEBO Reports 2004, 5:1-5.
41. Hall W., Carter L. Ethical issues in trialing and using a cocaine vaccine to treat and prevent cocaine addiction. Technical Report No. 140 2002, Available, Executive Summary. National Drug and Alcohol Research Centre, NSW, Australia. http://www.ndarc.med.unsw.edu.au/ndarc.nsf.
42. Hall W., Carter L. Ethical issues in using a cocaine vaccine to treat and prevent cocaine abuse and dependence. J Med Ethics 2004, 30:337-340.
43. Hall W., Madden P., Lynskey M. The genetics of tobacco use: methods, findings and policy implications. Tob Control 2002, 11:119-124.
44. Hall W., Carter L., Morley K. Addiction, neuroscience and ethics. Addiction 2003, 98:867-870.
45. Hall W., Carter L., Morley K. Addiction, ethics and freedom. Addiction 2003, 98:873-874.
46. Hall W., Carter L., Morley K. Neuroscience research on the addictions: a prospectus for future ethical and policy analysis. Addict Behav 2004, 29:1481-1495.
47. Hall W., Morley K., Lucke J. The prediction of disease risk in genomic medicine. EMBO Reports 2004, 5:S22-S26. (special issue).
48. Hampton T. Genes harbour clues to addiction, recovery. JAMA 2004, 292:321-322.
49. Hasman A., Holm S. Nicotine conjugate vaccine: is there a right to a smoking future?. J Med Ethics 2004, 30:344-345.
50. Husak D. The moral relevance of addiction. Subst Use Misuse 2004, 39:399-436.
51. Kantak K.M. Vaccines against drugs of abuse: a viable treatment option?. Drugs 2003, 63:341-352.
52. Kavanagh D., Andrade J., May J. Beating the urge: implications of research into substance-related desires. Addict Behav 2004, 29:1359-1372.
53. Khan K. Commentary: race, drugs and prevalence. Int J Drug Policy 1999, 10:83-88.
54. Kleiman M. The 'brain disease' idea, drug policy and research ethics. Addiction 2003, 98:871-872.
55. Lavine D. MR imaging of fetal central nervous system abnormalities. Brain Cognition 2002, 50:432-448.
56. Lerman C., Niaura R. Applying genetic approaches to the treatment of nicotine dependence. Oncogene 2002, 21:7412-7420.
57. Leshner A.I. Addiction is a brain disease and it matters. Science 1997, 278:45-47.
58. Leshner A.I., Koob G. Drugs of abuse and the brain. Proc Assoc Am Phys 1999, 111:99-108.
59. Marteau T., Lerman C. Genetic risk and behavioural change. BMJ 2001, 322:1056-1059.
60. Mason J., McCall Smith R., Laurie G. Law and medical ethics 2003, Lexis Nexis Butterworths, London. 6th edition.
61. McCrady B., Bux D. Ethical issues in informed consent with substance abusers. J Consult Clin Psychol 1999, 67:186-193.
62. McGregor I., Gallate J. Rats on the grog: novel pharmacotherapies for alcohol craving. Addict Behav 2004, 29:1341-1357.
63. McHarg A. Reconciling human rights and the public interests: conceptual problems and doctrinal uncertainty in the jurisprudence of the European Court of Human Rights. Modern Law Res 1999, 62:671-696.
64. Mohn A.R., Yao W.D., Caron M.G. Genetic and genomic approaches to reward and addiction. Neuropharmacology 2004, 47(Supplement 1):101-110.
65. Morse S. Hooked on hype: addiction and responsibility. Law Philos 2000, 19:3-9.
66. Morse S. Medicine and morals, craving and compulsion. Subst Use Misuse 2004, 39:437-460.
67. Murry T. Ethical issues in immunotherapies and depot medications for substance abuse. New treatment for addiction: behavioral, ethical, legal, and social questions 2004, 188-212. National Academies Press, Washington.
68. National Research Council (NRC) and the Institute of Medicine of the National Academies New treatments for addiction: behavioural, ethical, legal and social questions 2004, National Academies Press, Washington, DC.
69. National Institute for Clinical Excellence (NICE) 2002/021-NICE recommends use of smoking cessation therapies: press release. Thursday 11 April 2002.
70. Nestler E., Landsman D. Learning about addiction from the genome. Nature 2001, 409:834-835.
71. Newman R. Involuntary treatment for drug addiction. Addiction 1974, 113-126. Academic Press, New York. P.G. Bourne (Ed.).
72. Nuffield Council on Bioethics (NCB) Genetics and human behaviour: the ethical context 2002, Nuffield Council on Bioethics, London.
73. Nuffield Council on Bioethics (NCB) Pharmacogenetics: ethical issues 2003, Nuffield Council on Bioethics, London.
74. Nutt D. The neurochemistry of addiction. Hum Psychopharmacol 1997, 12:S53-S58.
75. Nutt D., Lingford-Hughes A. Infecting the brain to stop addiction?. Proc Nat Acad Sci 2004, 101:11193-11194.
76. O'Loughlin J., Paradis G., Kim W., DiFranza J., Meshefedjian G., McMillan-Davey E., Wong S., Hanley J., Tyndale R. Genetically decreased CYP2A6 and the risk, of tobacco dependence: a prospective study of novice smokers. Tobacco Control 2004, 13:422-428.
77. O'Neill O. Autonomy and trust in bioethics 2002, Cambridge University Press, Cambridge.
78. Richards T. Putting genetics in perspective. BMJ 2003, 322:1005-1006.
79. Richards T. Three views of genetics: the enthusiast, the visionary, and the sceptic. BMJ 2003, 322:1016-1017.
80. Ridgely M., Iguchi M., Chiesa J. The use of immunotherapies and sustained-released formulations in the treatment of drugs addiction: will current law support coercion?. New treatment for addiction: behavioral, ethical, legal, and social questions 2004, 173-187. National Academies Press, Washington.
81. Risch N., Burchard E., Ziv E., Tang H. Categorisation of humans in biochemical research: genes, race and disease. Genome Biol 2002, (3):1-12. comment2007.1-007.12, 7.
82. Roses A. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genetics 2004, 5:645-656.
83. Rowland A., Umbach D., Stallone L., Naftel A., Bohlig E., Sandler D. Prevalence of medication treatment for attention deficit hyperactivity disorder among elementary school children in Johnston County, North Carolina. Am J Public Health 2002, 92:231-234.
84. Sehgal A., Hall J. Herbal medicines: harmless or harmful?. Anaesthesia 2002, 57:947-948.
85. Shaw D., Kolev S., House I., Murray V. Should herbal medicines be licensed?. BMJ 1995, 311:451-452.
86. Solomon P., Adams F., Silver A., Zimmer J., DeVeaux R. Ginkgo for memory enhancement: a randomised controlled trial. J Am Med Assoc 2002, 288:835-840.
87. Sommerville A. Commentary: is testing for HIV without consent justifiable?. BMJ 2002, 325:1226-1227.
88. Stevenson D., Goldworth A. Ethical considerations in neuroimaging and its impact on decision-making for neonates. Brain Cognition 2002, 50:449-454.
89. Strang J., McCambridge J., Best D., Beswick T., Bearn J., Rees S., Gossop M. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow-up study. BMJ 2003, 326:959-960.
90. Ten C. Crime and punishment. A companion to ethics 2004, 366-372. Blackwell Publishing, Oxford. P. Singer (Ed.).
91. Terrenoire G. Huntington's disease and the ethics of genetic prediction. J Med Ethics 1992, 18:75-78.
92. Thun M., Henley S., Calle E. Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene 2002, 21:7307-7325.
93. Tyndale R.F. Genetics of alcohol and tobacco use in humans. Ann Med 2003, 35:94-121.
94. Uhl G.R. Are over-simplified views of addiction neuroscience providing too simplified ethical considerations?. Addiction 2003, 98:871-874.
95. Watson G. Excusing addiction. Law Philosophy 1999, 19:589-619.
96. Wolpe R. Treatment, enhancement, and the ethics of neurotherapeutics. Brain Cognition 2002, 50:387-395.
97. World Health Organisation (WHO) Neuroscience of psychoactive substance use and dependence 2004, WHO, Geneva.
98. Worthington C., Myers T. Factors underlying anxiety in HIV testing: risk perceptions, stigma, and the patient-provider power dynamic. Qual Health Res 2003, 13:636-655.
99. Wright A., Weinman J., Marteau T. The impact of learning of a genetic predisposition to nicotine dependence: an analogue study. Tobacco Control 2003, 12:227-230.